ISM9546 (VAV1 molecular glue degrader)
Insilico Medicine: company profile
Preclinical candidate per company
Since , the date of the source that reports this phase.
Summary
ISM9546 is a VAV1 molecular glue degrader from Insilico Medicine. The source describes it as small molecule (oral molecular glue). It is being developed for autoimmune diseases including rheumatoid arthritis and IBD. Per the company, it was at Preclinical candidate as of Oct 13, 2026. The AI role named in the source is molecule design. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Oct 13, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Autoimmune diseases including rheumatoid arthritis and IBD
- Therapeutic area
- Immunology and inflammation
- Modality
- Small molecule (oral molecular glue)
- AI role
- Molecule design
- Phase in the source
- Preclinical candidate, as of Oct 13, 2026
- Phase source
- X only
- Board column
- Preclinical
- Trial record
- none (preclinical)
AI evidence
AI source: Company
“Designed and optimized with AI, ISM9546”
Milestone timeline
-
Official X post: Preclinical candidate
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.